This result contributed to our understanding of protein acetylation regulation from the HDAC family, indicating that HDAC member-specific inhibitors would cause significant CML cancer cell death, as much as the apoptotic effect was due to treatment with pan-HDAC inhibitors. The gene discussed is HDAC9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.